EVIDENCE. COMPARISONS. CLEAR NEXT STEPS.FOR US CLINIC TEAMS PROCUREMENT RESEARCH
Next steps

What is the shortest defensible decision path?

Dose Diligence research deskSection 12 · Page 1 of 11Last updated 17 Nov 2026

Use six gates. A low price must not compensate for an unresolved route or quality concern.

GateQuestion to answerRecommended ownerEvidence required to advance
1. DefineAre we buying stock, appointing a dispenser or facilitating patient access?COO and financeRoute diagram, payer map and decision scope
2. QualifyIs the exact proposed arrangement supportable?Medical director and counselProduct-, facility-, state- and use-specific assessment
3. VerifyCan the partner support our patients and operating requirements?Procurement and pharmacy/quality leadDated evidence register and coverage matrix
4. CompareWhat does each equivalent scenario cost, and who pays?CFO and procurementMatched quotations and a transparent cost workbook
5. ProtectCan we manage failures, changes and an eventual exit?Counsel, operations and securityNegotiated obligations and transition responsibilities
6. ProveDoes the workflow work through dispensing and refill?Operations and clinical leadershipControlled pilot, exception log and go/no-go decision

If access is already failing, run continuity work in parallel. Assign an incident owner, identify affected prescriptions in the clinical system, contact the dispensing partner and escalate treatment questions to clinicians. Do not wait for a complete competitive procurement exercise—but do not treat urgency as permission to bypass the route and quality gates.

Explore the table row by row

A working view of the research

1. Define

Question to answer
Are we buying stock, appointing a dispenser or facilitating patient access?
Recommended owner
COO and finance
Evidence required to advance
Route diagram, payer map and decision scope

Sources cited on this page

    See the section’s source register for the research context.

    Section sources →